Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 443-459

  Vairappan, Balasubramaniyan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Asymmetric dimethylarginine; Endothelial function; Hepatic cirrhosis, reactive oxygen species; Inflammation; Nitric oxide; Portal hypertension

Indexed keywords

EID: 84928956636     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.443     Document Type: Article

References (204)

1. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 2004; 84: 869-901 [PMID: 15269339 DOI: 10.1152/physrev.00035.2003]
2. Inagami T, Naruse M, Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 1995; 57: 171-189 [PMID: 7778863 DOI:10.1146/annurev.ph.57.030195.001131]
3. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368 [PMID: 15668353 DOI:10.1161/01.CIR.0000153339.27064.14]
4. Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003; 108: 2049-2053 [PMID: 14581383 DOI: 10.1161/01.CIR.0000089507.19675.F9]
5. Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and inflammation: what is the link? Kidney Int Suppl 2003; (84): S45-S49 [PMID: 12694307]
6. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28:926-931 [PMID: 9755227 DOI: 10.1002/hep.510280405]
7. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010; 53: 558-567 [PMID: 20561700 DOI: 10.1016/j.jhep.2010.03.021]
8. Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, Moreau R, Jalan R. Inflammation and portal hypertension - the undiscovered country. J Hepatol 2014; 61: 155-163 [PMID:24657399 DOI: 10.1016/j.jhep.2014.03.014]
9. Goveia J, Stapor P, Carmeliet P. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol Med 2014; 6: 1105-1120 [PMID:25063693 DOI: 10.15252/emmm.201404156]
10. Strisciuglio T, De Luca S, Capuano E, Luciano R, Niglio T, Trimarco B, Galasso G. Endothelial dysfunction: its clinical value and methods of assessment. Curr Atheroscler Rep 2014; 16: 417 [PMID: 24764181 DOI: 10.1007/s11883-014-0417-1]
11. Mookerjee RP. Acute-on-chronic liver failure: the liver and portal haemodynamics. Curr Opin Crit Care 2011; 17: 170-176 [PMID:21346568 DOI: 10.1097/MCC.0b013e328344a076]
12. Mookerjee RP, Lackner C, Stauber R, Stadlbauer V, Deheragoda M, Aigelsreiter A, Jalan R. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011; 55: 1103-1111 [PMID: 21376092 DOI: 10.1016/ j.jhep.2011.02.021]
13. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007; 112: 265-280 [PMID: 17261089 DOI: 10.1042/CS20060242]
14. Mookerjee RP, Vairappan B, Jalan R. The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? Hepatology 2007; 46: 943-946 [PMID: 17879360 DOI: 10.1002/hep.21905]
15. Hsu SJ, Wang SS, Hsin IF, Lee FY, Huang HC, Huo TI, Lee WS, Lin HC, Lee SD. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci (Lond) 2014; 126: 633-644 [PMID:24063570 DOI: 10.1042/CS20130215]
16. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157 [PMID: 2971015]
17. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25:2-5 [PMID: 8985256 DOI: 10.1053/jhep.1997.v25.ajhep0250002]
18. Pechánová O, Simko F. The role of nitric oxide in the maintenance of vasoactive balance. Physiol Res 2007; 56 Suppl 2: S7-S16 [PMID:17824812]
19. Mookerjee RP, Balasubramaniyan V, Mehta G. ADMA and hepatic endothelial dysfunction in cirrhosis--the DDAH isoform is the key. Liver Int 2012; 32: 1186; author reply 1187 [PMID: 22574915 DOI:10.1111/j.1478-3231.2012.02814.x]
20. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, Duhamel C, Lebrec D, Poynard T, Moreau R. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-1882 [PMID: 17972337 DOI: 10.1002/hep.21920]
21. Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005; 25: 1079-1090 [PMID: 16343056 DOI: 10.1111/ j.1478-3231.2005.01163.x]
22. Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, MacAllister RJ. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 2004; 64: 172-178 [PMID: 15364625 DOI: 10.1016/j.cardiores.2004.06.020]
23. Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, Navarro-Zornoza M, Bosch J. New cellular and molecular targets for the treatment of portal hypertension. Hepatol Int 2015 Mar 5; Epub ahead of print [PMID: 25788198]
24. Bosch-Marcé M, Morales-Ruiz M, Jiménez W, Bordas N, Solé M, Ros J, Deulofeu R, Arroyo V, Rivera F, Rodés J. Increased renal expression of nitric oxide synthase type III in cirrhotic rats with ascites. Hepatology 1998; 27: 1191-1199 [PMID: 9581670 DOI:10.1002/hep.510270502]
25. Kakumitsu S, Shijo H, Yokoyama M, Kim T, Akiyoshi N, Ota K, Kubara K, Okumura M, Inoue K. Effects of L-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis. Hepatology 1998; 27: 377-382 [PMID: 9462634 DOI:10.1002/hep.510270210]
26. Balasubramaniyan V, Davies N, Daltan RN, Turner C, Williams R, Jalan R, Mook-erjee RP. The role of DDAH-ADMA in the regulation of hepatic eNOS activity in acute and chronic liver failure. Hepatology 2008; 48: 1045A
27. Balasubramaniyan V, Wright G, Sharma V, Davies NA, Sharifi Y, Habtesion A, Mookerjee RP, Jalan R. Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2012; 302: G145-G152 [PMID:21903766 DOI: 10.1152/ajpgi.00097.2011]
28. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, Groszmann RJ. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117:1222-1228 [PMID: 10535886]
29. Zimmermann K, Opitz N, Dedio J, Renne C, Muller-Esterl W, Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2002; 99: 17167-17172 [PMID: 12446846 DOI:10.1073/pnas.252345399]
30. Icking A, Matt S, Opitz N, Wiesenthal A, Müller-Esterl W, Schilling K. NOSTRIN functions as a homotrimeric adaptor protein facilitating internalization of eNOS. J Cell Sci 2005; 118:5059-5069 [PMID: 16234328 DOI: 10.1242/jcs.02620]
31. Icking A, Schilling K, Wiesenthal A, Opitz N, Müller-Esterl W. FCH/Cdc15 domain determines distinct subcellular localization of NOSTRIN. FEBS Lett 2006; 580: 223-228 [PMID: 16376344 DOI:10.1016/j.febslet.2005.11.078]
32. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, Sen S, Williams R, Leiper J, Vallance P, Jalan R. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45:62-71 [PMID: 17187433 DOI: 10.1002/hep.21491]
33. Vairappan B, Sharma V, Winstanley A, Davies N, Shah N, Jalan R, Mookerjee RP. Modulation of the DDAH-ADMA pathway with the Farnesoid receptor (FXR) agonist INT-747 restores hepatic eNOS activity and lowers portal pressure in cirrhotic rats. Hepatology 2009; 50: 336A-337A
34. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22:23-30 [PMID: 12553946]
35. Kasumov T, Edmison JM, Dasarathy S, Bennett C, Lopez R, Kalhan SC. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism 2011; 60: 776-781 [PMID: 20869086 DOI: 10.1016/ j.metabol.2010.07.027]
36. Vizzutti F, Romanelli RG, Arena U, Rega L, Brogi M, Calabresi C, Masini E, Tarquini R, Zipoli M, Boddi V, Marra F, Laffi G, Pinzani M. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 2007; 37: 509-515 [PMID:17537159 DOI: 10.1111/j.1365-2362.2007.01814.x]
37. Mookerjee RP, Dalton RN, Davies NA, Hodges SJ, Turner C, Williams R, Jalan R. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl 2007; 13: 400-405 [PMID: 17318866 DOI: 10.1002/lt.21053]
38. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-548 [PMID: 10690326]
39. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling:implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30: 1142-1150 [PMID: 19297385 DOI: 10.1093/ eurheartj/ehp061]
40. Abedini S, Meinitzer A, Holme I, März W, Weihrauch G, Fellstrøm B, Jardine A, Holdaas H. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010; 77: 44-50 [PMID: 19847152 DOI: 10.1038/ki.2009.382]
41. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O' Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13: 198-203 [PMID:17273169 DOI: 10.1038/nm1543]
42. Balasubramaniyan V, Sharma V, Metha G,Habtesion A, Turner C, Dalton RN, Davies N, Jalan R, Mookerjee RP. Acute lowering of portal pressure in cirrhotic rats by Anti-TNF therapy is associated with reduced NFkB-driven inflammation and improved eNOS function through the asymmetric dimethylargininedimethylarginine- diaminohydrolase axis. Gut 2010; 59 Suppl: A35 [DOI: 10.1136/gut.2010.223362.86]
43. Chen MF, Xie XM, Yang TL, Wang YJ, Zhang XH, Luo BL, Li YJ. Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res 2007; 44: 391-402 [PMID: 17551258 DOI: 10.1159/000103284]
44. Laleman W, Omasta A, Van de Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, Severi T, van Pelt J, Roskams T, Fevery J, Nevens F. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 2005; 42: 1382-1390 [PMID: 16317694 DOI: 10.1002/ hep.20968]
45. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-214 [PMID: 10493931]
46. Leiper JM. The DDAH-ADMA-NOS pathway. Ther Drug Monit 2005; 27: 744-746 [PMID: 16404814]
47. Balasubramaniyan V, Davies NA, Wright G, Dalton RN, Turner C, Williams R, Jalan R, Mookerjee RP. Treatment with Infliximab increases eNOS activity in cirrhosis through modulation of the DDAH-ADMA pathway. J Hepatol 2009; 50: S270
48. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99:3092-3095 [PMID: 10377069]
49. Forbes SP, Druhan LJ, Guzman JE, Parinandi N, Zhang L, Green-Church KB, Cardounel AJ. Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation. Biochemistry 2008; 47: 1819-1826 [PMID: 18171027 DOI: 10.1021/bi701659n]
50. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59: 2286-2298 [PMID: 24259407 DOI: 10.1002/hep.26939]
51. Laviña B, Gracia-Sancho J, Rodríguez-Vilarrupla A, Chu Y, Heistad DD, Bosch J, García-Pagán JC. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut 2009; 58: 118-125 [PMID: 18829979 DOI:10.1136/gut.2008.149880]
52. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, Rodrigo JM, Serra MA. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006; 231: 70-75 [PMID: 16380646]
53. Siroen MP, Wiest R, Richir MC, Teerlink T, Rauwerda JA, Drescher FT, Zorger N, van Leeuwen PA. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J Gastroenterol 2008; 14: 7214-7219 [PMID: 19084936]
54. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, Rodrigo JM. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004; 41: 55-59 [PMID: 15246208 DOI: 10.1016/ j.jhep.2004.03.016]
55. Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, García-Calderó H, Fernández M, Bosch J, García-Pagán JC. Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008; 47: 1248-1256 [PMID: 18273863 DOI: 10.1002/hep.22166]
56. Squadrito GL, Pryor WA. Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med 1998; 25: 392-403 [PMID: 9741578]
57. Lee JH, Yang ES, Park JW. Inactivation of NADP+-dependent isocitrate dehydrogenase by peroxynitrite. Implications for cytotoxicity and alcohol-induced liver injury. J Biol Chem 2003; 278: 51360-51371 [PMID: 14551203 DOI: 10.1074/jbc. M302332200]
58. Ridnour LA, Thomas DD, Mancardi D, Espey MG, Miranda KM, Paolocci N, Feelisch M, Fukuto J, Wink DA. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem 2004; 385: 1-10 [PMID: 14977040 DOI: 10.1515/ BC.2004.001]
59. Bec N, Gorren AFC B, Schmidt PP, Andersson KK, Lange R. The role of tetrahydrobiopterin in the activation of oxygen by nitricoxide synthase. J Inorg Biochem 2000; 81: 207-211 [PMID:11051565]
60. Vásquez-Vivar J, Whitsett J, Martásek P, Hogg N, Kalyanaraman B. Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. Free Radic Biol Med 2001; 31: 975-985 [PMID: 11595382]
61. Guillaume M, Rodriguez-Vilarrupla A, Gracia-Sancho J, Rosado E, Mancini A, Bosch J, Garcia-Pagán JC. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J Hepatol 2013; 58: 240-246 [PMID:22989570 DOI: 10.1016/j.jhep.2012.09.010]
62. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, Colomer D, Fernández M, Bosch J, Garcia-Pagán JC. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52 [PMID:16799985 DOI: 10.1002/hep.21228]
63. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, García-Calderó H, Fernández M, Bosch J, Garcia-Pagán JC. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. J Hepatol 2008; 49: 192-197 [PMID: 18534709 DOI: 10.1016/j.jhep.2008.04.014]
64. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81: 641-650 [PMID:7538909]
65. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010; 468: 1115-1118 [PMID: 21179168 DOI: 10.1038/ nature09599]
66. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33: 829-837, 837a-837d [PMID:21890489 DOI: 10.1093/eurheartj/ehr304]
67. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI:10.1016/j.cell.2009.12.052]
68. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012 [PMID: 7504210 DOI: 10.1056/ NEJM199312303292706]
69. Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE. Intraarterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003; 23: 695-701 [PMID:12692009 DOI: 10.1161/01.ATV.0000065195.22904.FA]
70. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19: 205-219 [PMID: 10422201 DOI: 10.1055/s-2007-1007110]
71. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920 [PMID: 2339855]
72. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, Boucher Y, Trebicka J, Trauner M, Angermayr B, Fuhrmann V, Reiberger T, Peck-Radosavljevic M. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. J Hepatol 2014; 60: 1135-1142 [PMID: 24530596 DOI: 10.1016/j.jhep.2014.01.025]
73. Heller J, Sogni P, Barrière E, Tazi KA, Chauvelot-Moachon L, Guimont MC, Bories PN, Poirel O, Moreau R, Lebrec D. Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376-381 [PMID: 11019992]
74. Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J, Hamilton JA, Bengmark S, Williams R, Visvanathan K. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003; 37:1154-1164 [PMID: 12717397 DOI: 10.1053/jhep.2003.50180]
75. Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003; 52: 1182-1187 [PMID: 12865279]
76. Bahcecioglu IH, Koca SS, Poyrazoglu OK, Yalniz M, Ozercan IH, Ustundag B, Sahin K, Dagli AF, Isik A. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachlorideinduced hepatic fibrosis. Inflammation 2008; 31: 215-221 [PMID:18427963 DOI: 10.1007/s10753-008-9067-1]
77. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194: 539-550 [PMID: 17761893 DOI: 10.1677/JOE-07-0234]
78. Balasubramaniyan V, Dhar DK, Warner AE, Vivien Li WY, Amiri AF, Bright B, Mookerjee RP, Davies NA, Becker DL, Jalan R. Importance of Connexin-43 based gap junction in cirrhosis and acute-on-chronic liver failure. J Hepatol 2013; 58: 1194-1200 [PMID: 23376361 DOI: 10.1016/j.jhep.2013.01.023]
79. Harry D, Anand R, Holt S, Davies S, Marley R, Fernando B, Goodier D, Moore K. Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic Rat. Hepatology 1999; 30: 1198-1205 [PMID: 10534341 DOI: 10.1002/hep.510300515]
80. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42: 985-990 [PMID:14557285 DOI: 10.1161/01.HYP.0000097805.05108.16]
81. Zhang GG, Bai YP, Chen MF, Shi RZ, Jiang DJ, Fu QM, Tan GS, Li YJ. Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. Vascul Pharmacol 2008; 48: 115-121 [PMID: 18295546 DOI: 10.1016/j.vph.2008.01.004]
82. Boya P, Larrea E, Sola I, Majano PL, Jiménez C, Civeira MP, Prieto J. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 2001; 34: 1041-1048 [PMID:11679977 DOI: 10.1053/jhep.2001.29002]
83. Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2006; 55: 542-546 [PMID: 16299035 DOI: 10.1136/ gut.2005.076562]
84. Jalan R, Olde Damink SW, Ter Steege JC, Redhead DN, Lee A, Hayes PC, Deutz NE. Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients. J Hepatol 2011; 54:265-271 [PMID: 21067839 DOI: 10.1016/j.jhep.2010.06.042]
85. Balasubramaniyan V, Davies N, Mookerjee R, Becker DL, Warner A, Jalan R. Inflammation upregulates hepatic connexin-43 expression in cirrhosis which defines susceptibility to development of acute-on chronic liver failure. J Hepatol 2012; 56: S236 [DOI:10.1016/S0168-8278(12)60608-4]
86. Wright G, Vairappan B, Stadlbauer V, Mookerjee RP, Davies NA, Jalan R. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver Int 2012; 32: 410-419 [PMID: 22151131 DOI:10.1111/j.1478-3231.2011.02698.x]
87. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009; 50: 1258-1266 [PMID:19398236 DOI: 10.1016/j.jhep.2009.03.007]
88. Hayashi T, Suzuki K. LPS-Toll-Like Receptor-Mediated Signaling on Expression of Protein S and C4b-Binding Protein in the Liver. Gastroenterol Res Pract 2010; 2010: pii: 189561 [PMID: 20827308 DOI: 10.1155/2010/189561]
89. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, Paradis V, Moore K, Mookerjee R, Jalan R. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 2013; 33: 398-409 [PMID:23402610 DOI: 10.1111/liv.12047]
90. Otsui K, Inoue N, Kobayashi S, Shiraki R, Honjo T, Takahashi M, Hirata K, Kawashima S, Yokoyama M. Enhanced expression of TLR4 in smooth muscle cells in human atherosclerotic coronary arteries. Heart Vessels 2007; 22: 416-422 [PMID: 18044001 DOI:10.1007/s00380-007-1001-1]
91. Freitas MR, Schott C, Corriu C, Sassard J, Stoclet JC, Andriantsitohaina R. Heterogeneity of endothelium-dependent vasorelaxation in conductance and resistance arteries from Lyon normotensive and hypertensive rats. J Hypertens 2003; 21: 1505-1512 [PMID:12872044 DOI: 10.1097/01.hjh.0000084713.53355.98]
92. Liang CF, Liu JT, Wang Y, Xu A, Vanhoutte PM. Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. Arterioscler Thromb Vasc Biol 2013; 33: 777-784 [PMID: 23413427 DOI: 10.1161/ ATVBAHA.112.301087]
93. Benhamou Y, Bellien J, Armengol G, Brakenhielm E, Adriouch S, Iacob M, Remy-Jouet I, Le Cam-Duchez V, Monteil C, Renet S, Jouen F, Drouot L, Menard JF, Borg JY, Thuillez C, Boyer O, Levesque H, Richard V, Joannidès R. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol 2014; 66: 3210-3220 [PMID: 25047402 DOI: 10.1002/art.38785]
94. Shah N, Dhar D, El Zahraa Mohammed F, Habtesion A, Davies NA, Jover-Cobos M, Macnaughtan J, Sharma V, Olde Damink SW, Mookerjee RP, Jalan R. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol 2012; 56: 1047-1053 [PMID: 22266601 DOI: 10.1016/j.jhep.2011.11.024]
95. Sun R, Zhu Z, Su Q, Li T, Song Q. Toll-like receptor 4 is involved in bacterial endotoxin-induced endothelial cell injury and SOCmediated calcium regulation. Cell Biol Int 2012; 36: 475-481 [PMID: 22288713 DOI: 10.1042/CBI20110535]
96. Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jürgens G, Hallström S, Jalan R. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G15-G22 [PMID:19033535 DOI: 10.1152/ajpgi.90512.2008]
97. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-1055 [PMID: 12717385 DOI: 10.1053/ jhep.2003.50182]
98. Martin-Armas M, Simon-Santamaria J, Pettersen I, Moens U, Smedsrød B, Sveinbjørnsson B. Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides. J Hepatol 2006; 44:939-946 [PMID: 16458386 DOI: 10.1016/j.jhep.2005.09.020]
99. Jagavelu K, Routray C, Shergill U, O'Hara SP, Faubion W, Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 2010; 52: 590-601 [PMID:20564354 DOI: 10.1002/hep.23739]
100. Benten D, Wiest R. Gut microbiome and intestinal barrier failure-- the "Achilles heel" in hepatology? J Hepatol 2012; 56: 1221-1223 [PMID: 22406521 DOI: 10.1016/j.jhep.2012.03.003]
101. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139: 186-193 [PMID: 12899586]
102. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923 [PMID:8621776 DOI: 10.1172/JCI118623]
103. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-750 [PMID: 11584371 DOI: 10.1053/ jhep.2001.28231]
104. Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, Walther T, Sauerbruch T, Burrell LM, Angus PW, Trebicka J. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 2013; 145: 874-884.e5 [PMID:23796456 DOI: 10.1053/j.gastro.2013.06.036]
105. Pugsley MK. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 2005; 48: 35-38 [PMID:16416656]
106. Locatelli F, Del Vecchio L, Cavalli A. Inhibition of the reninangiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract 2009; 113: c286-c293 [PMID: 19729963 DOI: 10.1159/000235946]
107. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Reninangiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001; 65: 775-778 [PMID: 11548874]
108. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: e5 [PMID: 15215814 DOI:10.1016/j.ahj.2004.03.025]
109. Liu H, Kitazato KT, Uno M, Yagi K, Kanematsu Y, Tamura T, Tada Y, Kinouchi T, Nagahiro S. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: invivo and in-vitro studies. J Hypertens 2008; 26: 1435-1445 [PMID:18551021 DOI: 10.1097/HJH.0b013e3283013b6e]
110. Graupera M, March S, Engel P, Rodés J, Bosch J, García-Pagán JC. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 2005; 288: G763-G770 [PMID:15550559 DOI: 10.1152/ajpgi.00300.2004]
111. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007; 132: 709-719 [PMID: 17258737 DOI:10.1053/j.gastro.2006.12.041]
112. Xavier FE, Blanco-Rivero J, Sastre E, Badimón L, Balfagón G. Simultaneous inhibition of TXA(2) and PGI(2) synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats. Clin Sci (Lond) 2010; 119: 283-292 [PMID: 20459396 DOI: 10.1042/ CS20090536]
113. Birney Y, Redmond EM, Sitzmann JV, Cahill PA. Eicosanoids in cirrhosis and portal hypertension. Prostaglandins Other Lipid Mediat 2003; 72: 3-18 [PMID: 14626493]
114. Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, Monclús M, Bosch J, García-Pagán JC. Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. J Cell Mol Med 2012; 16: 2461-2470 [PMID:22436078 DOI: 10.1111/j.1582-4934.2012.01563.x]
115. Dogné JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, Pirotte B, Ruan KH. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 2006; 12:903-923 [PMID: 16533159]
116. Gardi C, Arezzini B, Monaco B, De Montis MG, Vecchio D, Comporti M. F2-isoprostane receptors on hepatic stellate cells. Lab Invest 2008; 88: 124-131 [PMID: 18158556 DOI: 10.1038/ labinvest.3700712]
117. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008; 118: 18-35 [PMID: 18374420 DOI: 10.1016/j.pharmthera.2008.01.001]
118. Cimetière B, Dubuffet T, Muller O, Descombes JJ, Simonet S, Laubie M, Verbeuren TJ, Lavielle G. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 1998; 8:1375-1380 [PMID: 9871769]
119. Liu CQ, Leung FP, Wong SL, Wong WT, Lau CW, Lu L, Yao X, Yao T, Huang Y. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Pharmacol 2009; 78: 374-381 [PMID:19409373 DOI: 10.1016/j.bcp.2009.04.022]
120. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415 [PMID: 2451132 DOI: 10.1038/332411a0]
121. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007; 50: 621-628 [PMID:18091577 DOI: 10.1097/FJC.0b013e31813c6cc3]
122. Lee JY, Lee FY, Huo TI, Wang SS, Huang HC, Lin HC, Chuang CL, Lee SD. Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: association with the ETA receptor and pERK up-regulation. Liver Int 2015; 35: 704-712 [PMID:24636620 DOI: 10.1111/liv.12527]
123. Jiang ZY, Zhou QL, Chatterjee A, Feener EP, Myers MG, White MF, King GL. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999; 48: 1120-1130 [PMID: 10331419]
124. Juan CC, Fang VS, Huang YJ, Kwok CF, Hsu YP, Ho LT. Endothelin-1 induces insulin resistance in conscious rats. Biochem Biophys Res Commun 1996; 227: 694-699 [PMID: 8885996 DOI:10.1006/bbrc.1996.1571]
125. Berthiaume N, Carlson CJ, Rondinone CM, Zinker BA. Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats. Metabolism 2005; 54:1515-1523 [PMID: 16253642 DOI: 10.1016/j.metabol.2005.05.019]
126. Chuang CL, Huang HC, Chang CC, Lee FY, Wu JC, Lee JY, Hsieh HG, Lee SD. Lipopolysaccharide enhanced renal vascular response to endothelin-1 through ETA overexpression in portal hypertensive rats. J Gastroenterol Hepatol 2015; 30: 199-207 [PMID: 24989426 DOI: 10.1111/jgh.12670]
127. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectinlike, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006; 69: 36-45 [PMID: 16324688 DOI: 10.1016/ j.cardiores.2005.09.006]
128. Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 2013; 70: 2859-2872 [PMID: 23124189 DOI:10.1007/s00018-012-1194-z]
129. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H, Kataoka H, Nishi E, Horiuchi H, Arai H, Yokode M. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci 2001; 947: 199-205; discussion 205-206 [PMID: 11795267]
130. Lubrano V, Balzan S. LOX-1 and ROS, inseparable factors in the process of endothelial damage. Free Radic Res 2014; 48: 841-848 [PMID: 24886290 DOI: 10.3109/10715762.2014.929122]
131. Yin Y, Zhu QY, Ren SJ, Wang DM. Increased lectin-like oxidized LDL receptor-1 expression in the placentas of women with intrahepatic cholestasis during pregnancy. Clin Exp Obstet Gynecol 2012; 39: 149-152 [PMID: 22905453]
132. Musso G, Cassader M, De Michieli F, Saba F, Bo S, Gambino R. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 2011; 94: 1033-1042 [PMID: 21865331 DOI: 10.3945/ajcn.111.015610]
133. Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular biology. Vascul Pharmacol 2014; 62: 72-81 [PMID: 24924409 DOI: 10.1016/j.vph.2014.06.001]
134. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, Coughlin SR. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003; 102:3224-3231 [PMID: 12869501 DOI: 10.1182/blood-2003-04-1130]
135. Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S. A role for proteinaseactivated receptor-1 in inflammatory bowel diseases. J Clin Invest 2004; 114: 1444-1456 [PMID: 15545995 DOI: 10.1172/JCI21689]
136. Garcia JG, Patterson C, Bahler C, Aschner J, Hart CM, English D. Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J Cell Physiol 1993; 156: 541-549 [PMID: 8360259 DOI: 10.1002/ jcp.1041560313]
137. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in proteaseactivated receptor-1. Arterioscler Thromb Vasc Biol 1999; 19:3014-3024 [PMID: 10591683]
138. Knight V, Tchongue J, Lourensz D, Tipping P, Sievert W. Proteaseactivated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells. Hepatology 2012; 55:879-887 [PMID: 22095855 DOI: 10.1002/hep.24784]
139. Sakata K, Eda S, Lee ES, Hara M, Imoto M, Kojima S. Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β. Biochem Biophys Res Commun 2014; 443:950-956 [PMID: 24361885 DOI: 10.1016/j.bbrc.2013.12.074]
140. Silva TE, Colombo G, Schiavon LL. Adiponectin: A multitasking player in the field of liver diseases. Diabetes Metab 2014; 40:95-107 [PMID: 24486145 DOI: 10.1016/j.diabet.2013.11.004]
141. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026 [PMID:12944390 DOI: 10.1074/jbc.M307878200]
142. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51: 8-14 [PMID: 17998473 DOI:10.1161/HYPERTENSIONAHA.107.099424]
143. Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y, Christopher T, Lopez B, Chan L, Goldstein B, Ma XL. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009; 46: 413-419 [PMID: 19027750 DOI: 10.1016/ j.yjmcc.2008.10.014]
144. Tietge UJ, Böker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89 [PMID: 15010338 DOI:10.1152/ajpendo.00494.2003]
145. Salman TA, Allam N, Azab GI, Shaarawy AA, Hassouna MM, El-Haddad OM. Study of adiponectin in chronic liver disease and cholestasis. Hepatol Int 2010; 4: 767-774 [PMID: 21286349 DOI:10.1007/s12072-010-9216-0]
146. Tacke F, Wüstefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, Trautwein C, Brabant G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-673 [PMID: 15826715 DOI: 10.1016/j.jhep.2004.12.024]
147. Cash WJ, O'Neill S, O'Donnell ME, McCance DR, Young IS, McEneny J, McDougall NI, Callender ME. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013; 33: 1166-1174 [PMID: 23672463 DOI: 10.1111/ liv.12191]
148. Artwohl M, Roden M, Waldhäusl W, Freudenthaler A, Baumgartner-Parzer SM. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J 2004; 18: 146-148 [PMID: 14597560 DOI: 10.1096/fj.03-0301fje]
149. Khan MJ, Rizwan Alam M, Waldeck-Weiermair M, Karsten F, Groschner L, Riederer M, Hallström S, Rockenfeller P, Konya V, Heinemann A, Madeo F, Graier WF, Malli R. Inhibition of autophagy rescues palmitic acid-induced necroptosis of endothelial cells. J Biol Chem 2012; 287: 21110-21120 [PMID: 22556413 DOI:10.1074/jbc.M111.319129]
150. Staiger H, Staiger K, Stefan N, Wahl HG, Machicao F, Kellerer M, Häring HU. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes 2004; 53: 3209-3216 [PMID: 15561952]
151. Cacicedo JM, Benjachareowong S, Chou E, Ruderman NB, Ido Y. Palmitate-induced apoptosis in cultured bovine retinal pericytes:roles of NAD(P)H oxidase, oxidant stress, and ceramide. Diabetes 2005; 54: 1838-1845 [PMID: 15919807]
152. Ristić-Medić D, Takić M, Vučić V, Kandić D, Kostić N, Glibetić M. Abnormalities in the serum phospholipids fatty acid profile in patients with alcoholic liver cirrhosis - a pilot study. J Clin Biochem Nutr 2013; 53: 49-54 [PMID: 23874070 DOI: 10.3164/jcbn.12-79]
153. Okuda Y, Kawashima K, Sawada T, Tsurumaru K, Asano M, Suzuki S, Soma M, Nakajima T, Yamashita K. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun 1997; 232: 487-491 [PMID:9125207 DOI: 10.1006/bbrc.1997.6328]
154. Lee CH, Lee SD, Ou HC, Lai SC, Cheng YJ. Eicosapentaenoic acid protects against palmitic acid-induced endothelial dysfunction via activation of the AMPK/eNOS pathway. Int J Mol Sci 2014; 15:10334-10349 [PMID: 24918290 DOI: 10.3390/ijms150610334]
155. Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. Dig Dis Sci 2010; 55: 631-641 [PMID: 19856102 DOI: 10.1007/ s10620-009-1020-0]
156. Kajikawa S, Imada K, Takeuchi T, Shimizu Y, Kawashima A, Harada T, Mizuguchi K. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. Dig Dis Sci 2011; 56: 1065-1074 [PMID: 20848203 DOI:10.1007/s10620-010-1400-5]
157. Mandard S, Müller M, Kersten S. Peroxisome proliferatoractivated receptor alpha target genes. Cell Mol Life Sci 2004; 61:393-416 [PMID: 14999402 DOI: 10.1007/s00018-003-3216-3]
158. Rodríguez-Vilarrupla A, Laviña B, García-Calderó H, Russo L, Rosado E, Roglans N, Bosch J, García-Pagán JC. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol 2012; 56: 1033-1039 [PMID:22245887 DOI: 10.1016/j.jhep.2011.12.008]
159. Hernández-Guerra M, García-Pagán JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, Bosch J. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006; 43: 485-491 [PMID:16496307 DOI: 10.1002/hep.21080]
160. Yang YY, Lee TY, Huang YT, Chan CC, Yeh YC, Lee FY, Lee SD, Lin HC. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int 2012; 32: 48-57 [PMID: 22098317 DOI:10.1111/j.1478-3231.2011.02651.x]
161. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 2012; 302: E481-E495 [PMID: 22167522 DOI: 10.1152/ ajpendo.00540.2011]
162. Patanwala I, King MJ, Barrett DA, Rose J, Jackson R, Hudson M, Philo M, Dainty JR, Wright AJ, Finglas PM, Jones DE. Folic acid handling by the human gut: implications for food fortification and supplementation. Am J Clin Nutr 2014; 100: 593-599 [PMID:24944062 DOI: 10.3945/ajcn.113.080507]
163. García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, Bosch J, García-Pagán JC. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol 2011; 54: 660-665 [PMID: 21159403 DOI: 10.1016/j.jhep.2010.07.034]
164. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999; 100: 1050-1055 [PMID: 10477529]
165. Zenebe W, Pechánová O, Bernátová I. Protective effects of red wine polyphenolic compounds on the cardiovascular system. Exp Clin Cardiol 2001; 6: 153-158 [PMID: 20428452]
166. De Gottardi A, Berzigotti A, Seijo S, D'Amico M, Thormann W, Abraldes JG, García-Pagán JC, Bosch J. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis:results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr 2012; 96: 584-590 [PMID: 22811444 DOI: 10.3945/ ajcn.112.040469]
167. Lin SY, Wang YY, Chen WY, Chuang YH, Pan PH, Chen CJ. Beneficial effect of quercetin on cholestatic liver injury. J Nutr Biochem 2014; 25: 1183-1195 [PMID: 25108658 DOI: 10.1016/ j.jnutbio.2014.06.003]
168. Di Pascoli M, Diví M, Rodríguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, Bosch J, García-Pagán JC. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2013; 58:904-910 [PMID: 23262250 DOI: 10.1016/j.jhep.2012.12.012]
169. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-1658 [PMID: 19208350 DOI: 10.1053/j.gastro.2009.01.043]
170. Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W, Wascher TC, Trauner M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209: 178-183 [PMID:19782361 DOI: 10.1016/j.atherosclerosis.2009.08.052]
171. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, Rodés J, Bosch J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-755 [PMID:14988829]
172. Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, Colmenero J, Dominguez M, Egido J, Arroyo V, Ginès P, Bataller R. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009; 296: G147-G156 [PMID: 19056767 DOI: 10.1152/ ajpgi.00462.2007]
173. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256 [PMID: 19137587 DOI: 10.1002/ hep.22758]
174. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, Morales-Ruiz M. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926 [PMID: 17935226 DOI: 10.1002/hep.21921]
175. Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 2014; 61: 396-407 [PMID: 24751830 DOI: 10.1016/j.jhep.2014.04.012]
176. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 2004; 106: 467-474 [PMID: 14678008 DOI: 10.1042/ CS20030357]
177. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948 [PMID: 12297842 DOI:10.1053/jhep.2002.35819]
178. Kremer H, Baron-Menguy C, Tesse A, Gallois Y, Mercat A, Henrion D, Andriantsitohaina R, Asfar P, Meziani F. Human serum albumin improves endothelial dysfunction and survival during experimental endotoxemia: concentration-dependent properties. Crit Care Med 2011; 39: 1414-1422 [PMID: 21336119 DOI:10.1097/CCM.0b013e318211ff6e]
179. Dubois MJ, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, Brimioulle S, Appoloni O, Creteur J, Vincent JL. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med 2006; 34: 2536-2540 [PMID: 16915107 DOI: 10.1097/01.CCM.0000239119.57544.0C]
180. Corradi F, Brusasco C, Fernández J, Vila J, Ramirez MJ, Seva-Pereira T, Fernández-Varo G, Mosbah IB, Acevedo J, Silva A, Rocco PR, Pelosi P, Gines P, Navasa M. Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. Dig Liver Dis 2012; 44:239-244 [PMID: 22119621 DOI: 10.1016/j.dld.2011.10.014]
181. Lee PC, Yang YY, Huang CS, Hsieh SL, Lee KC, Hsieh YC, Lee TY, Lin HC. Concomitant inhibition of oxidative stress and angiogenesis by chronic hydrogen-rich saline and N-acetylcysteine treatments improves systemic, splanchnic and hepatic hemodynamics of cirrhotic rats. Hepatol Res 2014 Jun 24; Epub ahead of print [PMID: 24961937 DOI: 10.1111/hepr.12379]
182. Yang YY, Lee KC, Huang YT, Wang YW, Hou MC, Lee FY, Lin HC, Lee SD. Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis. J Hepatol 2008; 49:25-33 [PMID: 18490076 DOI: 10.1016/j.jhep.2008.02.012]
183. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29: 992-999 [PMID: 19210289 DOI:10.1111/j.1365-2036.2009.03958.x]
184. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogeninduced cholestasis. J Pharmacol Exp Ther 2005; 313: 604-612 [PMID: 15644430 DOI: 10.1124/jpet.104.079665]
185. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005; 315: 58-68 [PMID: 15980055 DOI: 10.1124/jpet.105.085597]
186. Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006; 281: 39831-39838 [PMID: 17065154 DOI: 10.1074/jbc.M606779200]
187. Mookerjee R, Rosselli M, Pieri G, Beecher-Jones T, Hooshmand-Rad R, Chouhan M, Mehta G, Jalan R, Shapiro D. Effect of the FXR Agonist Obeticholic acid on portal pressure in alcoholic cirrhosis: a proof of concept Phase 2a study. Hepatology 2012; 56:1529-1530 [DOI: 10.1016/S0168-8278(14)60017-9]
188. Mehta G, Sharma V, Habtesion A, Balasubramaniyan V, Davies N, Jalan R, Budhram-Mahadeo V, Mookerjee RP. Gene transfer of dimethylarginine dimethylaminohydrolase-1 reduces portal pressure in a rodent model of cirrhosis. Gut 2012; 61 Suppl 2: A123 [DOI:10.1136/gutjnl-2012-302514b.123]
189. Bosoi CR, Parent-Robitaille C, Anderson K, Tremblay M, Rose CF. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 2011; 53: 1995-2002 [PMID: 21384402 DOI: 10.1002/hep.24273]
190. Inami Y, Hamada C, Seto T, Hotta Y, Aruga S, Inuma J, Azuma K, Io H, Kaneko K, Watada H, Tomino Y. Effect of AST-120 on Endothelial Dysfunction in Adenine-Induced Uremic Rats. Int J Nephrol 2014; 2014: 164125 [PMID: 24829798 DOI:10.1155/2014/164125]
191. Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, Wu CH, Chiou TT, Lee YT, Liao SC. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. Blood Purif 2014; 37: 76-83 [PMID: 24576840 DOI: 10.1159/000357641]
192. Davies NA, Wright G, Ytrebø LM, Stadlbauer V, Fuskevåg OM, Zwingmann C, Davies DC, Habtesion A, Hodges SJ, Jalan R. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 2009; 50: 155-164 [PMID: 19437490 DOI: 10.1002/hep.22897]
193. Balasubramaniyan V, Davies N, Gavin W, Vikram S, Raj M, Rajiv J. L-ornithine phenylacetate (OCR-002) reduces portal pressure by modulating hepatic NFkB and hepatic eNOS activity in cirrhotic rats. Hepatology 2009; 50: 338A-340A
194. Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol:antifibrotic effects of carvedilol in chronic carbon tetrachlorideinduced liver damage. Toxicol Appl Pharmacol 2012; 261: 292-299 [PMID: 22543095 DOI: 10.1016/j.taap.2012.04.012]
195. Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver Int 2013; 33: 561-568 [PMID:23331709 DOI: 10.1111/liv.12101]
196. Ma L, Gul R, Habibi J, Yang M, Pulakat L, Whaley-Connell A, Ferrario CM, Sowers JR. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol 2012; 302: H2341-H2351 [PMID: 22447938 DOI: 10.1152/ ajpheart.01126.2011]
197. Pires MJ, Rodríguez-Peña AB, Arévalo M, Cenador B, Evangelista S, Esteller A, Sánchez-Rodríguez A, Colaço A, López-Novoa JM. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 2007; 25: 2486-2496 [PMID:17984671 DOI: 10.1097/HJH.0b013e3282efeecb]
198. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552-558 [PMID: 22278628 DOI: 10.1038/hr.2012.8]
199. Yasuno S, Fujimoto A, Nakagawa Y, Kuwahara K, Ueshima K. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther 2012; 10: 577-583 [PMID: 22651833 DOI: 10.1586/erc.12.34]
200. Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R, Saracco G, Rizzetto M, Marzano A. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-1033 [PMID: 17336417 DOI:10.1016/j.jhep.2007.01.017]
201. Vairappan B, Davies N, Sharma V, Shah N, Mookerjee RP, Jalan R. Reduction in hyperammonemia with L-ornithine phenylacetate (OCR-002) in bile-duct-ligated (BDL) cirrhoticrats restores brain eNOS activity by modulating the DDAH-ADMA pathway. Hepatology 2009; 476A
202. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, Bosch J. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46: 1040-1046 [PMID: 17335931 DOI:10.1016/j.jhep.2007.01.020]
203. La Mura V, Pasarín M, Meireles CZ, Miquel R, Rodríguez-Vilarrupla A, Hide D, Gracia-Sancho J, García-Pagán JC, Bosch J, Abraldes JG. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 2013; 57: 1172-1181 [PMID: 23184571 DOI: 10.1002/ hep.26127]
204. Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang YO, Yea CJ, Kim JW, Kim HS, Kwon SO, Yoo BS, Kim JY, Eom MS, Cha SH, Chang SJ. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. Liver Int 2012; 32: 977-987 [PMID:22364262 DOI: 10.1111/j.1478-3231.2012.02774.x]